sutures newsletter

PRODUCED BY AND FOR MEMBERS OF THE DEPARTMENT OF SURGERY November 2015 | Archived Issues

P & T Approvals, FDA Warning About Hepatitis Drugs, Statement About Plavix

Pharmacy Focus

See highlights of the October meeting of the Pharmacy and Therapeutics Committee. Also, the U.S. Food and Drug Administration has released a warning regarding the risk of serious liver injury with use of hepatitis treatments Viekira Pak and Technivie, and the agency says long-term use of Plavix does not change the risk of death for patients with heart disease.


Mark Your Calendar


Surgery Grand Rounds

Click the "read more" to see information about upcoming Surgery Grand Rounds.


Grand Rounds

Click here to view a schedule of all upcoming grand rounds.


Education Schedule

Click the PDF links below to see the Department of Surgery's education schedule.

Education Schedule - December 2015 (PDF)  


Surgery Scheduling

Click the "read more" for hours and contact information for surgery scheduling.

Share Your News

Know an interesting colleague we should profile? A story we should tell? Submit your ideas, meetings and events for consideration.

Click here to submit your news to Sutures

P & T Approvals, FDA Warning About Hepatitis Drugs, Statement About Plavix

Pharmacy Focus

Highlights of the October meeting of the Pharmacy and Therapeutics Committee are summarized in the PDF link below. Also, the U.S. Food and Drug Administration has released a warning regarding the risk of serious liver injury with use of hepatitis treatments Viekira Pak and Technivie, and the agency says long-term use of Plavix does not change the risk of death for patients with heart disease.

P&T Approvals - October 2015 (PDF)  

FDA: Risk of Liver Injury Possible with Hepatitis C Drugs

The U.S. Food and Drug Administration has released a warning regarding the risk of serious liver injury with use of the hepatitis C medications Viekira Pak and Technivie. The manufacturer, AbbVie, is being required to include information about these serious hepatic adverse events in the drug labels for these two combination products.

An FDA review identified cases of hepatic decompensation and liver failure in patients with underlying liver cirrhosis who were taking these medicines. Some of these events resulted in liver transplantation or death.

Viekira Pak is a combination of ombitasvir, paritaprevir, ritonavir and dasabuvir. Technivie is a combination of ombitasvir, paritaprevir and ritonavir.

For more information, click here.

FDA: Long-Term Use of Plavix Does Not Change Risk of Death

A review by the U.S. Food and Drug Administration has determined that long-term use of the blood-thinning drug Plavix (clopidogrel) does not increase or decrease overall risk of death in patients with, or at risk for, heart disease. FDA evaluation of several clinical trials also does not suggest that clopidogrel increases the risk of cancer or death from cancer.

The FDA analysis indicates that long-term (12 months or longer) dual antiplatelet therapy with clopidogrel and aspirin does not appear to change the overall risk of death when compared to short-term (six months or less) clopidogrel and aspirin, or aspirin alone. Also, there was no apparent increase in the risk of cancer-related deaths or cancer-related adverse events with long-term treatment.

For more information, click here.